Ad sense

Friday, February 27, 2015

Guided Therapeutics, Inc.

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its fourth quarter and year ended December 31, 2014 and provide an update on business activity on Wednesday, March 25, 2015, after the market closes.

Guided Therapeutics will hold a conference call at 11:00 a.m. EST Thursday, March 26, 2015, to discuss its financial results and corporate developments. Interested parties are invited to listen to the call live over the Internet at The live call is also available by dialing (888) 455-2263 or for international callers (719) 325-2435 and referencing Conference ID 5351293.

A replay of the teleconference will be available on A replay will also be available until May 2, 2015, by dialing (877) 870-5176 or for international callers (858) 384-5517 and using pin number 5351293.

The Company continues to work with government and non-governmental organizations in Asia, Latin America and Africa to expand access to LuViva. There are currently devices in 19 countries and distribution agreements that cover 52 countries. Current efforts are focused on closing large deals with ministries of health in the developing world where the product is being evaluated for primary screening. While it takes time to bring these deals to fruition, the Company believes the size of the deals has the potential to rapidly progress the company towards breakeven.

Guided Therapeutics currently has regulatory approval to sell LuViva in Europe with the Edition 3 CE mark, and has marketing approvals from COFEPRIS in Mexico, Health Canada and Singapore Health Sciences Authority, among others.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit:

The Guided Therapeutics LuViva(R) Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2013, and subsequent quarterly reports.

SOURCE: Guided Therapeutics, Inc.

Investors: Cameron Associates Alison Ziegler, 212-554-5469 or For Guided Therapeutics Bill Wells, 770-242-8723 Ext. 241

No comments:

Post a Comment